Abstract
Background Type 1 diabetes is an autoimmune disease, which leads to insulin dependence. We investigated genetic evidence to support the repurposing of seven drugs, already licensed or in clinical phases of development, for prevention of type 1 diabetes.
Methods We obtained genome-wide association study (GWAS) summary statistics for the risk of type 1 diabetes, whole-blood gene expression, and serum protein levels, and investigated genetic polymorphisms near seven potential drug target genes. We used colocalization to examine whether the same genetic variants that are associated with type 1 diabetes risk were also associated with the relevant drug target genetic proxies, and Mendelian randomization to evaluate the direction and magnitude of the associations. Furthermore, we performed Mendelian randomization analysis restricted to functional variants within the drug target genes.
Findings Colocalization revealed that the blood interleukin (IL)-2 receptor subunit alpha (IL2RA) and IL-6 receptor (IL6R) gene expression levels within the corresponding genes shared the same causal variant with type 1 diabetes liability (posterior probabilities 100% and 96.3%, respectively). Odds ratios (OR) of type 1 diabetes per 1-SD increase in the genetically proxied gene expression of IL2RA and IL6R were 0.22 (95% confidence interval [CI] 0.17-0.27) and 1.98 (95% CI 1.48-2.65), respectively. Using missense variants, genetically proxied tyrosine kinase 2 (TYK2) expression levels were associated with type 1 diabetes risk (OR 0.61, 95% CI [0.54-0.70]).
Interpretation Our findings support the targeting of IL-2, IL-6R and TYK2 signaling in prevention of type 1 diabetes. Further studies should assess the optimal window to intervene to prevent type 1 diabetes.
Funding Kyllikki ja Uolevi Lehikoisen säätiö, Foundation for Pediatric Research, Finnish Cultural Foundation, JDRF International; The University of Oulu & The Research Council of Finland Profi 326291; European Union’s Horizon 2020 research and innovation program under grant agreement no. 848158 (EarlyCause).
Evidence before this study We searched PubMed for GWAS, Mendelian randomization, colocalization, and other studies for genetic evidence of efficacy of targeting IL2RA, IL2RB, IL6R, IL6ST, IL23A, TYK2, JAK2, and JAK3 signaling in prevention of type 1 diabetes. We searched studies with combinations of “IL2RA”, “IL2RB”, “IL6R”, “IL6ST”, “IL23A”, “JAK2”, “JAK3”, “TYK2”, “colocalization”, "mendelian randomization", or “GWAS” and "Diabetes Mellitus, Type 1"[Mesh].
A recent large GWAS by Robertson et al. observed five conditionally independent genome-wide significant single-nucleotide polymorphisms (SNPs) associated with the risk of type 1 diabetes in intergenic and intronic areas near IL2RA. Another large recent GWAS by Chiou et al. found six independent SNPs associated with the risk of type 1 diabetes near IL2RA. A few smaller candidate gene studies also reported associations between the risk of type 1 diabetes and eight other loci near IL2RA. Epigenetic studies reported that a few type 1 diabetes risk variants near IL2RA are associated with changes in methylation of DNA near promoters of IL2RA in white blood cells and B-cells.
Both above mentioned GWAS found associations between two missense mutations in TYK2 gene (rs12720356(A>C), rs34536443(G>C)) and the risk of type 1 diabetes. The same variants protected against type 1 diabetes and some other autoimmune diseases in a Finnish FINNGEN biobank study. Smaller candidate gene studies found that the rs2304256 A/A genotype was protective against type 1 diabetes in a Southern Brazilian and in a European population. In a study of Japanese population, similar association was not seen, possibly due to differences in allele frequencies and incidence of type 1 diabetes between populations. In the same study, TYK2 promoter haplotype with genetic polymorphisms in promoter region and exon 1 decreased the promoter activity and increased the risk for type 1 diabetes. The minor 358Ala allele of the IL6R SNP rs2228145 (A>C) was found to be associated with a reduced risk of developing T1D.
In addition to loci near or at IL2RA and TYK2 loci, the GWAS by Robertson et al. reported an association between rs2229238 near IL6R and the risk of type 1 diabetes. Furthermore, a candidate gene study found that the GG haplotypes of variants rs11171806 and rs2066808 (in strong LD) near IL23A was protective against T1D.
We found no studies in which colocalization between the loci near the reviewed genes and type 1 diabetes was reported nor estimates from Mendelian randomization on the possible causal relationship. However, Robertson et al. studied the genetic evidence for therapeutic potential of their GWAS hits using a priority index algorithm, which combined information from GWAS of type 1 diabetes, expression quantitative loci in immune cells, evidence from chromatin conformation in immune cells, as well as protein-protein interactions and genomic annotations. Among the reported GWAS hits, priority index ranked IL2RA as the top target, followed by TYK2 (the 3rd target), JAK2 (11th), IL23 (25th), JAK3 (35th), and IL6R (50th).
Added value of this study We found that the risk of type 1 diabetes and whole-blood gene expression of IL2RA and IL6R colocalized to rs61839660 near IL2RA and rs10908839 near IL6R, respectively. Using these loci as instruments of IL2RA and IL6R expression, Mendelian randomization indicated that whole blood IL2RA expression is associated with decreased risk of type 1 diabetes (OR 0.70 per 1 SD increase) whereas IL6R expression is associated with increased risk (OR 1.079 per 1 SD increase). Furthermore, when a missense variant rs2304256 in TYK2 was used as an instrument for TYK2 expression, Mendelian randomization indicated that an SD increase in TYK2 expression was predicted to decrease the risk of type 1 diabetes (OR 0.61).
Implications of all the available evidence We found genetic evidence supporting the efficacy of targeting IL-2, IL-6 and TYK2 signalling in prevention of type 1 diabetes. Further research is needed to address when would be the most optimal time to intervene in the pathogenesis of type 1 diabetes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Kyllikki ja Uolevi Lehikoisen saatio, Foundation for Pediatric Research, Finnish Cultural Foundation, JDRF International; The University of Oulu & The Research Council of Finland Profi 326291; European Union's Horizon 2020 research and innovation program under grant agreement no. 848158 (EarlyCause).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We used publicly available summary data from published studies that obtained relevant ethical approval and participant consent. The code used to generate our results is available at https://github.com/jkoskenniemi/T1DSCREEN.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The code used to generate our results is available at https://github.com/jkoskenniemi/T1DSCREEN.
